Rohto Pharmaceutical Co.,Ltd.
Rohto Pharmaceutical Co., Ltd. 2027 Fiscal Year Q1 Consolidated Financial Results (Interim) (Consolidated)
Discloses trends in net sales and profits. For the consolidated results for the first quarter of the 2027 fiscal year, presents figures for net sales, operating income, and net income, by segment and for the company as a whole, with year-over-year comparisons. Reports demand trends post-COVID, the contribution of each segment, and references future outlook on the note page.
Key Figures
- Net sales: Unknown (no figures listed in the PDF)
- Operating income: Unknown (no figures listed in the PDF)
- Net income attributable to owners of the parent: Unknown (no figures listed in the PDF)
AI要約
Section Heading
In Rohto's first-quarter results, the overview of net sales, cost of sales, selling, general and administrative expenses, operating income, ordinary income, and quarterly net income is reported on a Japanese standards basis and on a consolidated basis. Looking at segment breakdowns, region-specific net sales for Japan, the United States, Europe, and Asia are disclosed, with explanations of currency effects, contributions from new products, and changes in demand. The financial results summary also includes notes on accounting policies, depreciation trends, and fair value changes of investment securities, alongside notes to the financial statements.
Section 2 Heading
As a summary of financial condition, disclosures cover the composition of current assets, fixed assets, and liabilities, and changes in major items. For capital policy, liquidity, and cash flows, the note outlines cash flows from investing and financing activities, movements in liabilities and net assets, and notes to the consolidated financial statements. For the outlook, updates to full-year guidance based on changing market conditions and segment-specific growth strategies are noted.
Rohto Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
